Probably the most sound and realistic post leaving
Post# of 157824
However, a word of caution nobody really knows what is going on and what will happen Monday. If we look to the past we will probably all agree that nothing exciting will happen.
At some point market moving news will drop. Cyrus was pretty clear about that yet the market does what it always does even though he’s thrown us a bone. “Catalyst driven year.” Cyrus has said it several times yet people are selling their shares. Pretty typical people will miss the boat unless you follow a stock very closely.
I guess I’ll remind people what Catalyst means, “A catalyst is anything that can bring in a drastic change in a stock's current trend.”
Anyone who believes this won’t happen clearly hasn’t followed the stock close enough. Monday what will happen. I have no idea, the stock could bounce off of .20 or it could shoot up to 3 dollars. Anyone who wants to say otherwise is completely clueless, lying or doesn’t invest in highly volatile stocks. Even worse they are just trying to take your shares before the news.
It’s only a matter of time. The question is when? Probably not during our quarterly CC but who really knows. Place your bets.


CytoDyn Inc (CYDY) Stock Research Links
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36